Department of Error

Choueiri TK, Albiges L, Barthélémy P, et al. Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study. Lancet 2024; 404: 1309–20—In figure 2 of this Article, the subheading Previous systemic anticancer therapies (line of therapy) has been corrected to read Line of therapy. In the second paragraph of the Results section, the second sentence has been corrected to read, “The most common previous systemic cancer therapies were ipilimumab–nivolumab and axitinib–pembrolizumab combinations in the first line and single-agent cabozantinib and single-agent nivolumab in the second line (appendix p 10); overall, 204 (60%) of 339 patients had received previous nivolumab either alone or in combination (appendix p 10)”. In the eighth paragraph of the Results section, the appendix page number in the first sentence has been updated to “p 12”. In the ninth paragraph of the Results section, the sixth sentence has been corrected to read, “The most common any-grade treatment-emergent adverse events (TEAEs) occurring in 10% or more of the patients were similar for both groups for hypertension (62 [37%] of 168 patients receiving tivozanib–nivolumab and 69 [40%] of 171 patients receiving tivozanib monotherapy) and diarrhoea (51 [30%] receiving tivozanib–nivolumab and 62 [36%] receiving tivozanib monotherapy; table 2)”. These corrections have been made to the online version as of Oct 3, 2024, and the printed version is correct.